Page All:
Page 1
Veeva Systems Introduces Global Key Opinion Leader (KOL) Data and Services Solution
BARCELONA, Spain, April 16, 2015 /PRNewswire/ --
New KOL solution - based upon newly acquired Qforma CrowdLink business - to
help life sciences companies drive more successful product launches
Veeva Systems (NYSE: VEEV) kicked off the ExL Pharma Medical Affairs Strategic Summit
this week unveiling Veeva KOL Data & Services
[http://eu.veeva.com/openkey/kol-data-and-services ], a new solution empowering life
sciences companies to better understand and engage stakeholders worldwide. It delivers
in-depth profiles of all relevant key opinion leaders (KOLs) and targeted engagement plans
for more successful product launches. Veeva's KOL solution builds on the recently acquired
Qforma CrowdLink KOL database, and leading segmentation and network visualisation
capabilities, providing the most sophisticated solution on the market today. The Qforma
Crowdlink team, now part of Veeva, brings specialised expertise in KOL data, analysis, and
engagement planning.
(Logo:
http://photos.prnewswire.com/prnh/20120425/527164 )
Two thirds of all pharmaceutical product launches today do not meet sales forecasts[i]
- a concern largely attributed to global market access restrictions, intensifying
regulatory pressure, and a rapidly changing provider landscape. Building trusted
relationships with all relevant stakeholders is critical to a successful launch. Veeva KOL
Data & Services provides the insights needed to identify and nurture the most important
relationships.
Veeva KOL Data & Services allows launch teams to accurately identify the right KOLs
around the world and maximise coverage. It also delivers in-depth KOL profiles to
personalise all interactions. Interactive relationship maps and hundreds of segmentation
overlays, coupled with expert services, help to develop highly targeted engagement plans
in each therapeutic area. All data is meticulously validated by specialised researchers
around the globe to ensure ongoing completeness and accuracy.
Kilian Weiss, founder of Mederi AG and former Qforma CEO, joins Veeva as general
manager of KOL Solutions with the acquisition of Qforma's Crowdlink KOL business. He
brings more than a decade of leadership in KOL data and services. "Clearly, communicating
value to patients, providers, and payers is critical to a successful launch," said Weiss.
"We are dedicated to helping the industry bring products to market with the most robust
KOL data and advisory services, on a global scale."
The Veeva KOL Data & Services solution, proven in more than 70 countries, provides
consistent data quality, compliance standards, and planning processes. This ensures
targeted and safe stakeholder engagement worldwide.
"Timely information on KOLs' activities and the latest developments in their
therapeutic area allows medical teams to be more relevant, valuable partners for KOLs and
enables manufacturers to forge sustainable relationships," added Marcus Bergler, globally
recognised expert in KOL strategy and Veeva's new European general manager for KOL
Solutions. "We deliver the data, innovative cloud technology, and expert services medical
teams need to create lifelong product advocates."
Veeva KOL General Manager Kilian Weiss will be presenting the new offering at ExL
Pharma's Medical Affairs Strategic Summit East on 17 April and the KOL Engagement and
Advisory Board Summit on 8 June. For more information, please email pr@veeva.com.
Additional Information:
- For more on Veeva KOL Data & Services, please visit: eu.veeva.com/KOLdata
[http://eu.veeva.com/openkey/kol-data-and-services ]
- Stay updated on the latest Veeva news on LinkedIn:
http://www.linkedin.com/company/veeva-systems
- Follow @veevasystems on Twitter: http://www.twitter.com/veevasystems
- Like Veeva on Facebook: http://www.facebook.com/veevasystems
[https://www.facebook.com/VeevaSystems ]
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences
industry. Committed to innovation, product excellence, and customer success, Veeva has
more than 275 customers, ranging from the world's largest pharmaceutical companies to
emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in
Europe, Asia, and Latin America. For more information, visit http://www.veeva.com.
New Veeva KOL Data & Services
It's global - worldwide coverage, consistent view of KOLs globally, yet tailored to
each local market's needs.
It's robust - provides accurate and compliant data about people, institutions,
activities, relationships, and sentiment.
It's actionable - Targeted engagement plans created for you. Further explore with easy
segmentation and dynamic visualisation of KOL networks.
Forward-looking Statements
This release contains forward-looking statements, including statements regarding
benefits from the use of Veeva's solutions, demand for Veeva's solutions, and general
business conditions. Any forward-looking statements contained in this press release are
based upon Veeva's historical performance and its current plans, estimates, and
expectations and are not a representation that such plans, estimates, or expectations will
be achieved. These forward-looking statements represent Veeva's expectations as of the
date of this press announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking statements in the future.
These forward-looking statements are subject to known and unknown risks and uncertainties
that may cause actual results to differ materially. Additional risks and uncertainties
that could affect Veeva's financial results are included under the captions "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition and Results of
Operations," in the company's filing on Form 10-K for the period ended January 31, 2015,
which is available on the company's website at http://www.veeva.com under the
Investors section and on the SEC's website at http://www.sec.gov. Further information
on potential risks that could affect actual results will be included in other filings
Veeva makes with the SEC from time to time.
[i] McKinsey & Company, "The secret of successful drug launches," by Hemant Ahlawat,
Giulia Chierchia, and Paul van Arkel, March 2014.
Photo:
http://photos.prnewswire.com/prnh/20120425/527164
Photo:http://photos.prnewswire.com/prnh/20120425/527164
http://photoarchive.ap.org/
Veeva Systems
CONTACT: Contact: Sue Glanville / Cate Bonthuys, Veeva Systems Inc., sue@catalystcomms.co.uk / cate@catalystcomms.co.uk, +44-(0)7715-817589 / +44-(0)7746-546773
Veeva Systems Introduces Global Key Opinion Leader (KOL) Data and Services Solution
BARCELONA, Spain, April 16, 2015 /PRNewswire/ --
New KOL solution - based upon newly acquired Qforma CrowdLink business - to
help life sciences companies drive more successful product launches
Veeva Systems (NYSE: VEEV) kicked off the ExL Pharma Medical Affairs Strategic Summit
this week unveiling Veeva KOL Data & Services
[http://eu.veeva.com/openkey/kol-data-and-services ], a new solution empowering life
sciences companies to better understand and engage stakeholders worldwide. It delivers
in-depth profiles of all relevant key opinion leaders (KOLs) and targeted engagement plans
for more successful product launches. Veeva's KOL solution builds on the recently acquired
Qforma CrowdLink KOL database, and leading segmentation and network visualisation
capabilities, providing the most sophisticated solution on the market today. The Qforma
Crowdlink team, now part of Veeva, brings specialised expertise in KOL data, analysis, and
engagement planning.
(Logo:
http://photos.prnewswire.com/prnh/20120425/527164 )
Two thirds of all pharmaceutical product launches today do not meet sales forecasts[i]
- a concern largely attributed to global market access restrictions, intensifying
regulatory pressure, and a rapidly changing provider landscape. Building trusted
relationships with all relevant stakeholders is critical to a successful launch. Veeva KOL
Data & Services provides the insights needed to identify and nurture the most important
relationships.
Veeva KOL Data & Services allows launch teams to accurately identify the right KOLs
around the world and maximise coverage. It also delivers in-depth KOL profiles to
personalise all interactions. Interactive relationship maps and hundreds of segmentation
overlays, coupled with expert services, help to develop highly targeted engagement plans
in each therapeutic area. All data is meticulously validated by specialised researchers
around the globe to ensure ongoing completeness and accuracy.
Kilian Weiss, founder of Mederi AG and former Qforma CEO, joins Veeva as general
manager of KOL Solutions with the acquisition of Qforma's Crowdlink KOL business. He
brings more than a decade of leadership in KOL data and services. "Clearly, communicating
value to patients, providers, and payers is critical to a successful launch," said Weiss.
"We are dedicated to helping the industry bring products to market with the most robust
KOL data and advisory services, on a global scale."
The Veeva KOL Data & Services solution, proven in more than 70 countries, provides
consistent data quality, compliance standards, and planning processes. This ensures
targeted and safe stakeholder engagement worldwide.
"Timely information on KOLs' activities and the latest developments in their
therapeutic area allows medical teams to be more relevant, valuable partners for KOLs and
enables manufacturers to forge sustainable relationships," added Marcus Bergler, globally
recognised expert in KOL strategy and Veeva's new European general manager for KOL
Solutions. "We deliver the data, innovative cloud technology, and expert services medical
teams need to create lifelong product advocates."
Veeva KOL General Manager Kilian Weiss will be presenting the new offering at ExL
Pharma's Medical Affairs Strategic Summit East on 17 April and the KOL Engagement and
Advisory Board Summit on 8 June. For more information, please email pr@veeva.com.
Additional Information:
- For more on Veeva KOL Data & Services, please visit: eu.veeva.com/KOLdata
[http://eu.veeva.com/openkey/kol-data-and-services ]
- Stay updated on the latest Veeva news on LinkedIn:
http://www.linkedin.com/company/veeva-systems
- Follow @veevasystems on Twitter: http://www.twitter.com/veevasystems
- Like Veeva on Facebook: http://www.facebook.com/veevasystems
[https://www.facebook.com/VeevaSystems ]
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences
industry. Committed to innovation, product excellence, and customer success, Veeva has
more than 275 customers, ranging from the world's largest pharmaceutical companies to
emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in
Europe, Asia, and Latin America. For more information, visit http://www.veeva.com.
New Veeva KOL Data & Services
It's global - worldwide coverage, consistent view of KOLs globally, yet tailored to
each local market's needs.
It's robust - provides accurate and compliant data about people, institutions,
activities, relationships, and sentiment.
It's actionable - Targeted engagement plans created for you. Further explore with easy
segmentation and dynamic visualisation of KOL networks.
Forward-looking Statements
This release contains forward-looking statements, including statements regarding
benefits from the use of Veeva's solutions, demand for Veeva's solutions, and general
business conditions. Any forward-looking statements contained in this press release are
based upon Veeva's historical performance and its current plans, estimates, and
expectations and are not a representation that such plans, estimates, or expectations will
be achieved. These forward-looking statements represent Veeva's expectations as of the
date of this press announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking statements in the future.
These forward-looking statements are subject to known and unknown risks and uncertainties
that may cause actual results to differ materially. Additional risks and uncertainties
that could affect Veeva's financial results are included under the captions "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition and Results of
Operations," in the company's filing on Form 10-K for the period ended January 31, 2015,
which is available on the company's website at http://www.veeva.com under the
Investors section and on the SEC's website at http://www.sec.gov. Further information
on potential risks that could affect actual results will be included in other filings
Veeva makes with the SEC from time to time.
[i] McKinsey & Company, "The secret of successful drug launches," by Hemant Ahlawat,
Giulia Chierchia, and Paul van Arkel, March 2014.
Photo:
http://photos.prnewswire.com/prnh/20120425/527164
Photo:http://photos.prnewswire.com/prnh/20120425/527164
http://photoarchive.ap.org/
Veeva Systems
CONTACT: Contact: Sue Glanville / Cate Bonthuys, Veeva Systems Inc., sue@catalystcomms.co.uk / cate@catalystcomms.co.uk, +44-(0)7715-817589 / +44-(0)7746-546773